Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

12.93USD
24 May 2017
Change (% chg)

$-0.38 (-2.86%)
Prev Close
$13.31
Open
$13.22
Day's High
$13.33
Day's Low
$12.75
Volume
2,832,454
Avg. Vol
3,620,200
52-wk High
$32.74
52-wk Low
$8.32

VRX.N

Chart for VRX.N

About

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment,... (more)

Overall

Beta: -0.38
Market Cap(Mil.): $4,417.90
Shares Outstanding(Mil.): 341.19
Dividend: --
Yield (%): --

Financials

  VRX.N Industry Sector
P/E (TTM): -- 14.29 17.36
EPS (TTM): -4.04 -- --
ROI: -3.42 -7.57 -5.72
ROE: -29.48 -7.17 -5.10

BRIEF-EyeGate receives milestone payment from Valeant

* EyeGate receives milestone payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients

May 22 2017

Humbled by Valeant, Ackman goes back to basics

LAS VEGAS Bill Ackman said on Thursday he is poised to go on a great investment run after a humiliating bet forced his hedge fund firm to return to basics.

May 18 2017

UPDATE 1-Humbled by Valeant, Ackman goes back to basics

LAS VEGAS, May 18 Bill Ackman said on Thursday he is poised to go on a great investment run after a humiliating bet forced his hedge fund firm to return to basics.

May 18 2017

BRIEF-Salix, Valeant and Actavis agree to stay outstanding litigation

* Statement regarding XiFaxan intellectual property litigation

May 17 2017

ValueAct practices what it preaches on succession

NEW YORK (Reuters Breakingviews) - Jeffrey Ubben has long been a different kind of activist investor. The ValueAct Capital founder largely avoids the limelight and mostly works with companies behind the scenes to improve performance, often focusing heavily on corporate governance. Now Ubben is practicing what he preaches by triggering his own orderly succession.

May 16 2017

BRIEF-Pershing Square Capital Management dissolves sole share stake in Valeant Pharmaceuticals

* Pershing Square Capital Management dissolves sole share stake in Valeant Pharmaceuticals International Inc - SEC filing

May 15 2017

BRIEF-COSMO announces having filed for arbitration seeking termination of license and supply agreement with Valeant

* ANNOUNCES HAVING FILED FOR ARBITRATION SEEKING TERMINATION OF LICENSE AND SUPPLY AGREEMENT WITH VALEANT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 12 2017

BRIEF-Valeant says may initiate additional cost savings programs to streamline its operations and eliminate redundant processes and expenses

* Valeant - Company continues to evaluate opportunities to improve its operating results and may initiate additional cost savings programs

May 09 2017

Drugmaker Valeant raises profit forecast; shares spike

Canada's Valeant Pharmaceuticals International Inc raised its 2017 earnings forecast and reported its first profit in six quarters, helped by a one-time tax gain, and its U.S. shares jumped nearly 21 percent.

May 09 2017

UPDATE 3-Drugmaker Valeant raises profit forecast; shares spike

* Shares up nearly 21 percent (Adds CEO and analyst comments, stock move)

May 09 2017

More From Around the Web

Earnings vs. Estimates